Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$60 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.4
Industry P/E
--
EV/EBITDA
0.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$0.6
EPS
$-0.7
Face value
--
Shares outstanding
72,292,859
CFO
$-234.61 Mln
EBITDA
$-297.26 Mln
Net Profit
$-266.15 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
InflaRx N.V. - ADR
| -9.7 | -0.8 | -9.7 | -13.1 | -22.2 | -25.7 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
InflaRx N.V. - ADR
| -59.1 | -47.4 | -34.9 | -5.4 | 27.0 | -89.1 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
InflaRx N.V. - ADR
|
0.9 | 60.1 | 0.0 | -43.8 | -173,594.0 | -85.1 | -- | 1.4 |
| 3.8 | 1,234.9 | 4.1 | -660.1 | -2,789.5 | -390.4 | -- | 7.7 | |
| 1.7 | 159.1 | 15.3 | -40.5 | -271.2 | -58.8 | -- | 2.9 | |
| 41.0 | 8,102.9 | 2,090.0 | 424.9 | 25.0 | 11.6 | 19.3 | 2.1 | |
| 17.2 | 921.1 | 16.1 | -199.0 | -975.8 | -207.1 | -- | 5.1 |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory... diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany. Address: Winzerlaer Str. 2, Jena, Germany, 07745 Read more
Co-Founder, CEO & Executive Director
Dr. Niels C. Riedemann M.D., Ph.D.
Co-Founder, CEO & Executive Director
Dr. Niels C. Riedemann M.D., Ph.D.
Headquarters
Jena
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of InflaRx NV - ADR is $0.91 (NASDAQ) as of 02-Apr-2026 16:00 EDT. InflaRx NV - ADR has given a return of -22.23% in the last 3 years.
Since, TTM earnings of InflaRx NV - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.55
|
1.64
|
|
2024
|
-3.16
|
2.37
|
|
2023
|
-2.25
|
0.94
|
|
2022
|
-4.42
|
1.55
|
|
2021
|
-3.67
|
1.88
|
The 52-week high and low of InflaRx NV - ADR are Rs 1.94 and Rs 0.71 as of 03-Apr-2026.
InflaRx NV - ADR has a market capitalisation of $ 60 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in InflaRx NV - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.01
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.